Parsons Capital Management Inc. RI purchased a new position in shares of Bioverativ Inc (NASDAQ:BIVV) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 15,882 shares of the biotechnology company’s stock, valued at approximately $906,000.
A number of other large investors have also modified their holdings of BIVV. TCI Wealth Advisors Inc. purchased a new stake in Bioverativ during the third quarter worth about $186,000. Reliance Trust Co. of Delaware purchased a new stake in Bioverativ during the third quarter worth about $249,000. Whittier Trust Co. of Nevada Inc. purchased a new stake in Bioverativ during the third quarter worth about $293,000. Raymond James Trust N.A. purchased a new stake in Bioverativ during the third quarter worth about $297,000. Finally, Oakbrook Investments LLC purchased a new stake in Bioverativ during the third quarter worth about $327,000. Institutional investors own 92.93% of the company’s stock.
In other Bioverativ news, Director Brian S. Posner acquired 1,000 shares of the company’s stock in a transaction on Wednesday, August 9th. The shares were bought at an average cost of $59.19 per share, for a total transaction of $59,190.00. Following the acquisition, the director now directly owns 6,693 shares of the company’s stock, valued at $396,158.67. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Louis J. Paglia acquired 2,000 shares of the company’s stock in a transaction on Monday, August 7th. The shares were acquired at an average price of $59.70 per share, for a total transaction of $119,400.00. Following the completion of the acquisition, the director now directly owns 5,056 shares in the company, valued at $301,843.20. The disclosure for this purchase can be found here.
A number of analysts have issued reports on BIVV shares. Zacks Investment Research upgraded shares of Bioverativ from a “hold” rating to a “strong-buy” rating and set a $73.00 price target on the stock in a research note on Tuesday, July 25th. Royal Bank Of Canada started coverage on shares of Bioverativ in a research note on Thursday, September 14th. They set a “sector perform” rating and a $59.00 price target on the stock. Evercore ISI started coverage on shares of Bioverativ in a research note on Wednesday, August 16th. They set an “in-line” rating and a $58.00 price target on the stock. Piper Jaffray Companies reiterated an “overweight” rating and set a $71.00 price target on shares of Bioverativ in a research note on Monday, October 23rd. Finally, Cowen and Company upgraded shares of Bioverativ from a “market perform” rating to an “outperform” rating in a research note on Monday, July 10th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. Bioverativ presently has an average rating of “Buy” and a consensus target price of $61.73.
Bioverativ Inc (BIVV) traded down 0.86% during mid-day trading on Monday, hitting $55.36. 726,637 shares of the company were exchanged. The firm has a 50 day moving average price of $57.77 and a 200 day moving average price of $58.01. The stock has a market cap of $5.99 billion and a price-to-earnings ratio of 13.16. Bioverativ Inc has a 12 month low of $40.00 and a 12 month high of $64.41.
Bioverativ (NASDAQ:BIVV) last announced its earnings results on Thursday, October 26th. The biotechnology company reported $0.80 EPS for the quarter, beating the consensus estimate of $0.55 by $0.25. The company had revenue of $291.60 million for the quarter, compared to analysts’ expectations of $285.45 million. The company’s quarterly revenue was up 27.2% on a year-over-year basis. Analysts anticipate that Bioverativ Inc will post $2.94 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This article was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.com-unik.info/2017/10/30/15882-shares-in-bioverativ-inc-bivv-purchased-by-parsons-capital-management-inc-ri.html.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Want to see what other hedge funds are holding BIVV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioverativ Inc (NASDAQ:BIVV).
What are top analysts saying about Bioverativ Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bioverativ Inc and related companies.